Athena’s Second submission in Canada with Zolpidem Sublingual ODT
Athena DDS, a technology driven company specialized in Oral Solid Dosage forms, announces yet another
submission of Zolpidem 5 & 10 mg Sublingual ODT.
‘With this submission Athena adds another product in Canada after successfully launching Ondansetron
ODT in 2015. This opens more opportunities for us in Canadian Market with the help of our partner’
enunciates Alexandre Williams, Managing director of Athena DDS.
For more information, please contact:
About Athena DDS:
Athena with its EU GMP approved facility and state of art R&D Centre is focused on the innovative and
value-added products in mature and emerging markets and is engaged in Licensing and Development model
for Specialty Pharma, Multinationals and other established companies. Athena provides comprehensive
product lifecycle management solutions for Oral Solids based on its proprietary technology platforms.
Athena has already developed many innovative products CTD format viz., Domperidone ODT, Fenofibrate
Capsule, Levocetirizine ODT, Meloxicam ODT, Metformin SR Tablets, Ondansetron ODT, Secnidazole
High Dose Sachet as one-shot treatment, Racecadotril Sachets, Tramadol Paracetamol ODT & Tablet,
Voglibose ODT and Zolpidem ODT & SL ODT. These products are already marketed by leading companies
across geographies or are under registration.
For further information, please visit www.athenadds.com